Oncology

• 

  All Medical News

  ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

  Written by Lorraine Carolan | 11 Feb 2016

• 

  All Medical News

  ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

  Written by Lorraine Carolan | 10 Feb 2016

  Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

• 

  All Medical News

  ASH 2015: Video Interview by Esther Drain. Myeloma XI initial response data at ASH. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) discusses the initial response data from Myeloma XI and whether early intensive therapy is the way forward in managing myeloma, with comment also from Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA).

  Written by Lorraine Carolan | 9 Feb 2016

• 

  All Medical News

  ASH 2015: Myeloma X (intensive) trial update: Professor Gordon Cook (Leeds Teaching Hospitals, UK) gives an update on Myeloma X and discusses the role of transplant in myeloma in the age of novel agents

  Written by Lorraine Carolan | 5 Feb 2016

• 

  All Medical News

  ASH 2015: Professor Antonio Palumbo (University of Torino, Italy), Dr Shaji Kumar (Mayo Clinic, Rochester, USA), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) give their highlights.

  Written by Lorraine Carolan | 4 Feb 2016

• 

  All Medical News

  ASH 2015 Video Interview by Esther Drain: Association of gene expression profiling, Interim PET, EBV status and PD-L1 expression in cHL. An interview with Dr Cathy Burton (Clinical Haematologist, Leeds Teaching Hospitals, UK)

  Written by Lorraine Carolan | 27 Jan 2016

• 

  All Medical News

  ASH 2015 Video Interview by Esther Drain: Is oral as effective as IV or sub cutaneous administration? Professor Philippe Moreau (University Hospital, Nantes, France), Professor Gordon Cook (Leeds Teaching Hospitals, UK) and Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discuss whether the trend towards new oral agents for myeloma will mean a choice between efficacy and convenience… or in fact whether both can be achieved

  Written by Lorraine Carolan | 26 Jan 2016

• 

  All Medical News

  ASH 2015: TOURMALINE: Professor Philippe Moreau (University Hospital, Nantes, France) discusses the Tourmaline study – ixazomib, lenalidomide, dexamethasone (iRd) in R/R myeloma, with opinions on the data from Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK), Professor Gordon Cook (Leeds Teaching Hospitals, UK), Erik Low (Chief Executive Myeloma UK) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA)

  Written by Lorraine Carolan | 25 Jan 2016

  Ixazomib improves progression-free survival across subgroups by Thomas R. Collins: The oral proteasome inhibitor (PI) ixazomib with lenalidomide and dexamethasone (IRd) performed well versus placebo plus lenalidomide and… read more.

• 

  All Medical News

  ASH 2015 Video Interview by Esther Drain: Erik Low (Chief Executive Myeloma UK), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) discuss how and when we might expect our patients to have access to the therapies now available to US myeloma patients

  Written by Lorraine Carolan | 22 Jan 2016

• 

  All Medical News

  ASH 2015: Clinical discussant in this ASH/FDA session, Professor Paul Richardson (Harvard medical School, Boston, USA), discusses the clinical relevance of the new oral proteazome inhibitor ixazomib and two new monoclonal antibodies daratumumab and elotuzumab approved in the last few weeks by the FDA

  Written by Lorraine Carolan | 21 Jan 2016

  Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.

• 

  All Medical News

  ASH 2015: Interview with Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA, USA) gives a flavour of the excitement generated at ASH

  Written by Lorraine Carolan | 20 Jan 2016

  ASH 2015 proved to be all that we’d hoped for! We’ve witnessed unprecedented change in multiple myeloma with CR and VGPR percentages higher than ever… and most of this… read more.

• 

  All Medical News

  ASH 2015: New therapies explored in peripheral T-cell lymphoma

  Written by Lorraine Carolan | 19 Jan 2016

  by Thomas R. Collins: In early results, patients newly diagnosed with peripheral T-cell lymphoma (PTCL) treated with the HDAC-inhibitor belinostat, and CHOP therapy, tolerated the combination well at… read more.